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Abstract
Objectives The primary objective was to investigate the prevalence of neuropathic-like pain in patients with psoriatic arthritis
(PsA). Secondary outcomes were to investigate whether mood, fatigue, pain, disease severity and fibromyalgia are associated
with neuropathic-like pain in PsA patients.
Methods PsA patients were assessed for fatigue, mood, pain, disease activity and fibromyalgia using questionnaires.
Neuropathic-like pain was assessed by PainDetect.
Results Sixty-four patients with PsAwere recruited from the Rheumatology Outpatient Department. Of the 64 patients recruited,
26.6% had ‘likely neuropathic pain’ and 21.9% had ‘possible neuropathic-like pain’ according to the PainDetect questionnaire.
Patients with ‘likely neuropathic pain’ had higher disease activity, health assessment questionnaire, patient global self-assessment
score, tender and swollen joint counts, dactylitis, enthesitis, pain severity and interference with day-to-day activities, fatigue
severity and impact, fibromyalgia, anxiety and depression than ‘unlikely neuropathic pain’ patients (p < 0.05). PainDetect score
correlated with measures of disease activity, fatigue, depression, anxiety, Widespread Pain Index and Symptom Severity Scale
(all p < 0.05). Most patients (71%) with neuropathic-like pain fulfilled American College of Rheumatology 2010 fibromyalgia
criteria. Patients with ‘possible neuropathic-like pain’ had scores between patients with ‘likely neuropathic pain’ and ‘unlikely
neuropathic pain’.
Conclusion Neuropathic-like pain as evidence of abnormal pain processing is common in patients with PsA. It is associated with
higher disease activity and fibromyalgia. A significant proportion of patients had ‘possible neuropathic-like’ pain with interme-
diate disease and symptom score suggesting neuropathic-like pain as evidence of abnormal pain processing is a continuum rather
than concurrent fibromyalgia.
Key Points
• Neuropathic pain is prevalent in psoriatic arthritis.
• Higher levels of pain, disease activity, fatigue, depression, anxiety and comorbidities in Psoriatic arthritis.
• Increased pain severity is associated with increased disease activity, fatigue, depression and anxiety.
Keywords Anxiety . Depression . Disease activity . Fatigue . Inflammatory arthritis . Neuropathic pain . Pain . PainDetect . Pain
severity . Psoriatic arthritis
Introduction
Pain is the most common complaint in patients with muscu-
loskeletal diseases. Patients with inflammatory arthritis (IA)
such as rheumatoid arthritis (RA) ranked pain as the most
important symptom [1], which has a major detrimental impact
on their quality of life [2]. Despite advances in treatment for
RA, many patients still suffer from pain [3].
Pain can be categorised into inflammatory, nociceptive and
neuropathic [4]. Inflammation leads to the release of prosta-
glandin E2 and prostaglandin I2 which can sensitise
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nociceptors on sensory neurones to induce pain. In contrast,
neuropathic pain is a type of pathological pain [5] and defined
as “pain initiated or caused by a primary lesion or dysfunction
in the nervous system” [6]. It can affect both the peripheral
and central nervous system and may be caused by a variety of
pathophysiological mechanisms such as inflammatory reac-
tions and neuroplastic changes [7]. It is characterised by sen-
sory abnormalities ranging from numbness to hypersensitivity
(hyperalgesia/allodynia) [8], which can be objectively
assessed by quantitative sensory testing (QST) which is a
non-invasive method to quantify sensory nerve function, by
quantifying the stimulus needed to elicit the perception of
specific types of sensation. QST allows for quantification of
assessment of perception thresholds for light touch, vibration,
thermal and pain sensation [9].
Abnormal pain processing in the central nervous system,
central sensitization, has been demonstrated consistently in
neuropathic pain [10]. Central sensitization occurs when no-
ciceptive stimulation results in increased excitability of neu-
rons in pain pathways, resulting in pain hypersensitivity, in-
cluding allodynia and hyperalgesia [5]. Central sensitization
has also been demonstrated in rheumatic diseases such as RA
[11, 12]. In a previous study investigating the prevalence of
neuropathic pain in RA, the most commonly identified neu-
ropathic pain features were ‘pain attacks like electric shocks’
and ‘pain with slight pressure’ [11].
Patients with neuropathic pain typically experience pain
that becomes chronic and less responsive to analgesic medi-
cation, as well as sleep disturbance, anxiety, depression and
reduced quality of life compared with patients with chronic,
non-neuropathic pain [13]. In addition to the negative effects
in the individual with neuropathic pain, there are also negative
effects on society—increased healthcare costs (increasedmed-
ication needs, increased visits to healthcare providers) and loss
of ability to work [14]. Neuropathic pain is in general under-
diagnosed and undertreated. Even when diagnosed, it can of-
ten be mismanaged—these patients are frequently prescribed
conventional analgesics such as non-steroidal anti-inflamma-
tories which have limited efficacy in managing neuropathic
pain [15], similarly opiates may not optimally manage neuro-
pathic pain due to resistance or insensitivity [5]. Neuropathic
pain is typically treated with antidepressants and anticonvul-
sants but may also benefit from psychological and occupation-
al therapies to help the patient cope with the pain [5], as even
when managed with appropriate pharmacology, benefits may
be limited [5, 15]. Understanding the cause, mechanism and
symptoms experienced is key to selecting, and future devel-
opment, of appropriate management of neuropathic pain [5].
The definition of neuropathic pain does not distinguish it
from pain arising from neuroplastic changes associated with
central sensitization so will be referred to as neuropathic-like
pain. Of the inflammatory arthritides, studies to date of
neuropathic-like pain have focused on RA; however, psoriatic
arthritis (PsA) is another common form of inflammatory ar-
thritis, but neuropathic-like pain and central sensitization have
not been assessed in these patients and may impact on disease
assessment similarly to RA. The aim of this study is to deter-
mine the prevalence of neuropathic-like pain and central sen-
s i t i z a t i o n u s i n g p r e s s u r e p a i n t h r e s h o l d a nd
mechanonociception testing [16]—and PainDetect question-
naire [17] in patients with PsA. The impact of neuropathic-like
pain and central sensitization on comorbidities (depression,
anxiety) and disease activity assessment will also be assessed.
Methods
During an eight-week period in 2017, all patients with PsA
being treated at the Rheumatology department based at the
Cardiff and the Vale University Health Board Trust were in-
vited to take part in the study, either by post or in person by the
study faculty when attending routine appointments at rheuma-
tology clinics. Patients were eligible to be included in the
study if they had a clinical diagnosis of PsA, were aged eigh-
teen or over and consented to being included in this study.
Patients were only excluded if they had phantom limb syn-
drome or complex regional pain syndrome or did not consent
to taking part in the study.
The patients who were enrolled in this study completed a
consent form, demographics form (component questions
detailed under demographics section of Table 1) and a series
of validated questionnaires (Table 1) [18–26], following
which they underwent pressure pain threshold and
mechanonociception testing and physical examination for
enthesitis and dactylitis, on the day of presenting to the unit.
The questionnaires were chosen to assess comorbidities and
outcome measures that are known to affect pain experience.
No follow-up was performed.
The PainDetect questionnaire results classified the patients
as ‘unlikely neuropathic’, ‘possible neuropathic’ or ‘neuro-
pathic’ groups. Secondary outcome measures included dis-
ease activity assessment, brief pain inventory score, tender
and swollen joint count, examination for dactylitis and
enthesitis, American College of Rheumatology (ACR) 2010
fibromyalgia (FM) questionnaire score, hospital anxiety and
depression scale, fatigue severity score and fatigue impact
scale.
Objective assessment of pressure pain threshold and
mechanonociception was conducted using an electronic
algometer (Somedic Algometer, Somedic SenseLab AB,
Sösdala, Sweden) [27] and von Frey filaments (North Coast
Medical Inc., Morgan Hill, California) [28].
von Frey filament testing was carried out on the mid-point
between the wrist and elbow on the anterior surface of the
forearms and on the skin over the medial end of the spine of
each scapula to elicit the mechanical nociceptive threshold
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and the mechanical pressure sensation threshold. Electronic
algometer testing was carried out at the mid-point of the ante-
rior surface of the thigh and the medial end of the spine of
scapulae, to elicit the pressure pain threshold (PPT). For elec-
tronic algometer testing and von Frey Filament testing, an
average of three measurements taken were recorded—since
multiple measurements are needed to reliably estimate the
threshold being assessed [16], but considering the time taken
for the full assessment for each patient for this study, it was
decided to be acceptable to complete three measurements for
pragmatic reasons.
The data was analysed using IBM SPSS Statistics for
Windows, V23.0. Armonk, NY: IBM Corp. The data was
tested for normality using Shapiro-Wilk. The results for all
groups at baseline were analysed using ANOVA and post-
hoc analysis using Dunnett’s test and then using independent
samples t test or independent samples Mann-Whitney U test
as appropriate, to analyse for significant differences. Pearson
coefficient correlation testing was carried out to analyse how
the parameters assessed varied with ‘pain severity’ and ‘the
PainDetect score’.
The study was approved by the South East Coast -
Brighton and Sussex Research Ethics Committee (17/LO/
0147).
Results
Sixty-four patients with a clinical diagnosis of PsA, aged >
18 years old, were recruited; their demographics are described
in Table 2. From their PainDetect score, seventeen (26.6%)
patients were classified into the ‘likely neuropathic pain’ (NP)
group, fourteen (21.9%) patients were classified into the ‘pos-
sible neuropathic pain’ (PNP) group and 33 (51.6%) patients
were classified into the ‘unlikely neuropathic pain’ (UNP)
group. In the NP and PNP groups, the majority of patients
were female, compared with UNP group, where the majority
of patients were male. Disease duration was longest and the
number of concomitant diseases was highest in the NP and
PNP groups compared with the UNP group, although these
differences were not significant (p = 0.161 and 0.077). On
average, the NP group was taking significantly more medica-
tions than the PNP and UNP groups (p = 0.025). There were
58 different comorbidities found in the patients enrolled, 15
seen in more than one patient, of which the most common
were hypertension (31.0%), type 2 diabetes (13.8%), psoriasis
(13.8%) and depression (10.3%).
Disease activity as measured by tender and swollen joint
counts, pain score, patient global assessment, dactylitis and
enthesitis scores were statistically significantly higher in the
NP than that in the UNP group (Table 2). There were also
statistically significant differences in these disease activity as-
sessments in PNP versus UNP except for enthesitis and
dactylitis, although for the latter the difference only just failed
to reach statistical significance (p = 0.057). Across the three
groups, disease activity was trending higher over the 3 cate-
gories, from unlikely neuropathic pain, to possible neuropath-
ic pain, to likely neuropathic pain [29].
Similarly to disease activity, patients with NP and PNP
were statistically significantly more likely have greater pain
Table 1 Assessments and questionnaires conducted on each participant in the study
Assessment Outcome assessed Primary or secondary
outcome
Consent form Consent n/a
Demographics form Demographics (age, sex, disease duration,
number of concomitant diseases, number
of medications)
n/a
American College of Rheumatology
2010 fibromyalgia criteria [18, 19]




Brief Pain Inventory [20] Pain severity, pain interference Secondary
Fatigue Impact Scale [21] Fatigue impact Secondary
Fatigue Severity Scale [22] Fatigue severity Secondary
Hospital Anxiety Depression Scale [23] Anxiety, depression Secondary
Health Assessment Questionnaire [24] Disability Index Secondary
Pain Detect Questionnaire [25] Pain type Primary
Patient Disease Activity
Assessment Questionnaire [26]
PDAS score, tender joint count,
swollen joint count
Secondary
Physical examination Enthesitis, dactylitis Secondary
Electronic algometer testing [27] Pressure pain threshold Secondary
von Frey filament testing [28] Mechanical nociceptive threshold Secondary
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interference and impact, more severe fatigue and higher levels
of anxiety and depression than UNP patients (Table 1).
Using the American College of Rheumatology 2010 fibro-
myalg ia (ACR2010FM) ques t ionnai re to assess
“fibromyalgianess” (which can be assessed as a continuum
as per the Polysymptomatic Distress Scale score [19]), accord-
ing to the Widespread Pain Index (WPI), pain was significant-
ly more widespread in the NP group. However, it did not
significantly differ between the PNP and UNP groups. Both
NP and PNP patients had statistically significantly higher
Symptom Severity Scale (SSS), scores than UNP patients.
The Polysymptomatic Distress Scale (PDS) scores indicated
a significantly greater degree of “fibromyalgianess” in the NP
group compared with the UNP group, with no significant dif-
ference between the PNP and UNP groups. Twenty patients (5
in UNP, 3 in PNP and 12 in NP) fulfilled ACR2010 criteria for
the diagnosis of FM.
Overall PainDetect score correlated positively with mea-
sures of disease activity and associated symptoms as well as
ACR2010FM PDS score and its components, WPI and SSS
(Table 3).
Mechanical nociception as assessed by von Frey filaments
were similar across 3 groups. PPT evaluated by electronic
algometer was lowest in NP patients than that in UNP or
PNP patients, but not significantly (Table 1). As PainDetect
scores increased, PPT scores decreased (Table 3), indicating
Table 2 Demographics and











Number (%) 33 (51.6%) 14 (21.9%) 17 (26.6%) NS
Age in years, mean (SD) 50.9 (14.9) 49.5 (9.8) 51.4 (16.7) NS
Female, N (%) 12 (36.4) 9 (64.3) 11 (64.7) NS
Disease duration in years, mean
(SD)
10.8 (8.5) 14.4 (15.3) 17.4 (13.7) NS
Number of concomitant diseases,
mean (SD)
1.5 (1.6) 1.6 (1.8) 2.9 (3.1) NS
Number of medications, mean (SD) 4.5 (2.6) 4.9 (2.9) 7.4 (5.0)* < 0.05
Assessments mean (SD)
Disease activities
Tender joint count 5.2 (5.5) 9.9 (4.8)* 13.2 (7.7)* < 0.001
Swollen joint count 2.6 (3.7) 6.9 (5.8)* 7.4 (6.8)* 0.003
Patient global assessment score
(0–10 cm)
0.92 (0.76) 1.95 (0.90)* 2.29 (1.38)* < 0.001
Pain severity (0–10 cm) 2.7 (2.2) 4.5 (2.0)* 5.9 (2.0)* < 0.001
Dactylitis score 1.4 (1.4) 3.8 (3.2) 3.8 (2.0)* < 0.001
Enthesitis score 1.5 (1.5) 2.2 (1.8) 2.9 (1.7)* 0.015
HAQ score 0.4 (0.5) 1.1 (0.8)* 1.5 (0.8)* < 0.001
Other symptoms
Pain interference 2.6 (2.6) 5.0 (2.6) 6.0 (2.0) < 0.001
Fatigue Impact Scale 29.3 (21.6) 47.6 (13.3)* 55.7 (17.6)* < 0.001
Fatigue Severity Scale 3.3 (1.8) 5.5 (1.0)* 5.4 (1.7)* < 0.001
Anxiety 7.1 (4.1) 9.6 (4.7) 10.9 (5.2)* 0.037
Depression 4.5 (4.4) 7.0 (3.4) 9.3 (4.0)* 0.001
ACR2010FM: Widespread Pain
Index
2.9 (3.2) 3.4 (2.6) 7.2 (4.5)* < 0.001
ACRFM2010: Symptom Severity
Scale (SSS)
3.8 (2.8) 6.4 (2.3)* 8.1 (2.7)* < 0.001
CRFM2010: Polysymptomatic
Distress Scale (PDS)
6.8 (5.2) 9.8 (4.5) 15.4 (6.3)* < 0.001
Quantitative sensory testing
von Frey filaments, mean (SD) 4.61 (0.5) 4.63 (0.4) 4.71 (0.4) NS
Algometer, mean (SD) 641 (236) 626 (380) 558 (334) NS
*p < 0.05 when compared with unlikely neuropathic pain group based on Dunnett’s t test post ANOVA. NS, not
significant
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an element of central sensitization, a mechanism in the devel-
opment of neuropathic pain [30].
Discussion
The results of this study suggest there is a high prevalence of
neuropathic-like pain (27%) and possible neuropathic pain
(22%) in PsA patients. These patients experience greater
levels of pain, and all measures of disease activity were higher.
This is similar to a Danish study by Rifbjerg-Madsen et al.
[31] investigating the prevalence of neuropathic pain in pa-
tients with RA, PsA and other spondyloarthritidies using the
PainDetect score, which found a prevalence of neuropathic
pain in PsA of 28%, which was significantly higher than the
two other types of arthritis investigated. Patients with NP have
higher fatigue, anxiety and depression scores. Similar to our
results, a large transatlantic study by Taylor et al. [3] in RA
patients found that patients with NP having significantly
higher pain severity and measures of disease activity. Their
study also showed that pain levels were related to fatigue
levels and severe pain to be associated with depression.
A limitation of this study may be that our sample popula-
tion included patients with FM—while only one patient stated
they had FM in the demographics questionnaire, according to
the ACR 2010 FM criteria [32] there were 20 patients with
fibromyalgia (NN 5, PN 3, LNP 12), suggesting that concom-
itant fibromyalgia is under-diagnosed in patients with PsA.
The PainDetect tool has been shown to not be as useful at
identifying neuropathic pain in patients with FM [33].
Significantly higher prevalence of FM has been found in
PsA patients compared with non-PsA individuals [34], and
FM has been found to be associated with worse PsA disease
activity [35]. It is also interesting to note that patients with
primary FM and psoriasis may be mistaken for patients with
PsA due to the similarity in presentation [36]. Patients with
neuropathic pain and patients with FM can describe similar
sensory perceptions—including burning and prickling pain
and allodynia [37]. Not excluding PsA patients with fibromy-
algia, or not creating a separate group for such patients, does
not permit evaluation of the effect of fibromyalgia on neuro-
pathic pain, for example, whether PsA and fibromyalgia in the
same patient may have an additive effect and lead to worse
neuropathic pain. Previous studies investigating the preva-
lence of neuropathic pain, as identified by the PainDetect
score, in patients with fibromyalgia and chronic widespread
pain found that the majority of these patients have neuropathic
pain [38, 39].
Another limitation of this study was the inclusion of pa-
tients with type 2 diabetes. Diabetic neuropathy is a common
complication of diabetes, which has a varying prevalence de-
pending on the definition of diabetic neuropathy, but affects a
greater proportion of diabetics as the time post diagnosis in-
creases [40]. In industrialised countries, diabetic neuropathy is
the most common type of neuropathy and neuropathic pain is
a common occurrence in length-dependent diabetic neuropa-
thy (diabetic neuropathy with an initial predilection for longer
neurons before shorter neurons, affecting 80% of diabetic neu-
ropathy) [41]. Painful diabetic neuropathy has been shown to
affect 1/3 of community-based diabetics in a large English
population, with having type 2 diabetes being one of the fac-
tors of patients with diabetes in whom painful diabetic neu-
ropathy was more prevalent [42]. Diabetic peripheral neurop-
athy is one of a number of causes of neuropathic pain, which
can be detected as probable neuropathic pain using the
PainDetect score (44) (other causes of neuropathic pain in-
clude chronic lower back pain, post-surgical neuropathy, post
trauma neuropathy, HIV, trigeminal neuralgia, post-herpetic
neuralgia [13, 43]). A previous study found an increased prev-
alence of diabetes in patients with PsA compared with non-
PsA patients and suggested that PsA may have an association
with diabetes in females, in particular [44]. Similarly to FM,
by not excluding or creating a separate group for the PsA
patients with diabetes, it is not possible to assess whether
having diabetes has an effect on the neuropathic pain experi-
enced by PsA patients. The demographic data of this study
found diabetes was the second most prevalent co-morbidity in
the study population.
A study investigating the similarities and differences of
diabetic painful neuropathy and FM found that both groups
of patients describe their pain as burning/prickling pain with
light touch allodynia [37], which has similarities to the char-
acteristics of neuropathic pain described in inflammatory
Table 3 Pearson correlation between PainDetect score with disease
activity and associated symptoms
Assessment parameter Pearson correlation p value
Widespread Pain Index 0.416 0.001
Symptom Severity Scale (SSS) 0.643 0.000
Polysymptomatic Distress Scale 0.592 0.000
HAQ score 0.624 0.000
Patient assessment score 0.526 0.000
Tender joint count 0.556 0.000
Swollen joint count 0.351 0.005
Pain severity 0.631 0.000
Pain interference 0.620 0.000
Fatigue Impact Scale 0.583 0.000




Dactylitis score 0.508 0.000
Enthesitis score 0.475 0.000
Pressure pain threshold − 0.320 0.010
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arthritides [11]. While this means that some of the results of
the investigations in this study may be secondary to diabetes,
in particular type 2 diabetes, and FM, rather than purely PsA,
not excluding patients with these conditions makes the study
population more similar to the UK population of patients with
PsA. This gives our results higher external validity, and an
indication that individuals in this population have a prevalence
of conditions that may contribute to neuropathic pain.
A key strength of this study was assessing these patients
with the ACR2010FM questionnaire. The majority of NP pa-
tients (12/17, 71%) fulfilled the criteria for FM. One may
interpret our data as evidence of concurrent unrecognised
FM in patients with PsA—the prevalence of FM in patients
with PsA (20/64, 31%) is much higher than that in the general
population of 5% [45]. Furthermore, patients with PNP seem
to represent an intermediate “fibromyalgic” phenotype. Only
3 out of 14 patients (21%) fulfilled ACR2010 criteria for FM.
Yet their pain severity, disease activity and associated symp-
toms, WPI and SSS were higher than those of UNP patients.
The correlation between PainDetect score with pain severity,
measures of disease activity, fatigue, depression, anxiety,
WPI, SSS, and PPT strongly suggests a continuum rather than
2 distinct populations of patients. Our interpretation is that
“fibromyalgianess” in PsA is a continuum and represents ab-
normal pain processing in patients experiencing chronic noci-
ceptive pain.
The weaknesses of this study include lack of a control group
to compare the study groups with, but as a preliminary study, this
is acceptable as the researchers were looking to see if a pattern
exists which could be tested more robustly in future. The sample
size of this study is relatively small so negative results may be
due to a lack of statistical power. Lack of follow-up data meant
that the stability of neuropathic pain phenotypes cannot be eval-
uated. It is also unclear whether more active disease predisposes
toNP/fibromyalgia ormeasures of disease activity are erroneous-
ly higher in patients with NP/fibromyalgia.
Conclusion
There is a high prevalence of neuropathic-like pain in psoriatic
arthritis. The causes of this are unknown, and a better under-
standing of how this develops may help develop better treat-
ments for PsA patients in the future.
PsA patients are severely affected by a variety of symptoms
beyond pain and disease activity, which have detrimental
biopsychosocial effects. This indicates that their care must
be tailored to address all of these problems experienced to
achieve the most effective management and therefore best
possible quality of life.
Acknowledgements The CREATE Centre was funded by Arthritis
Research UK and Health and Care Research Wales.
Compliance with ethical standards
Disclosures None.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Heiberg T, Kvien TK (2002) Preferences for improved health ex-
amined in 1,024 patients with rheumatoid arthritis: pain has highest
priority. Arthritis Rheum 47(4):391–397
2. Atzeni F, Masala IF, Salaffi F, Di Franco M, Casale R, Sarzi-Puttini
P (2015) Pain in systemic inflammatory rheumatic diseases. Best
Pract Res Clin Rheumatol 29(1):42–52
3. Taylor P, Manger B, Alvaro-Gracia J, Johnstone R, Gomez-Reino J,
Eberhardt E, Wolfe F, Schwartzman S, Furfaro N, Kavanaugh A
(2010) Patient perceptions concerning pain management in the
treatment of rheumatoid arthritis. J Int Med Res 38(4):1213–1224
4. McDougall JJ (2006) Arthritis and pain. Neurogenic origin of joint
pain. Arthritis Res Ther 8(6):220
5. Woolf CJ, Mannion RJ (1999) Neuropathic pain: aetiology, symp-
toms, mechanisms, and management. Lancet 353(9168):1959–
1964
6. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO,
Griffin JWet al (2008) Neuropathic pain: redefinition and a grading
system for clinical and research purposes. Neurology 70(18):1630–
1635
7. Baron R (2006) Mechanisms of disease: neuropathic pain—a clin-
ical perspective. Nat Rev Neurol 2(2):95
8. Garland EL (2012) Pain processing in the human nervous system: a
selective review of nociceptive and biobehavioral pathways. Prim
Care 39(3):561–571
9. Siao P, Cros DP (2003) Quantitative sensory testing. Phys Med
Rehabil Clin N Am 14(2):261–286
10. Melzack R, Coderre TJ, Katz J, Vaccarino AL (2001) Central
neuroplasticity and pathological pain. Ann N Y Acad Sci 933:
157–174
11. Koop SM, ten Klooster PM, Vonkeman HE, Steunebrink LM, van
de Laar MA (2015) Neuropathic-like pain features and cross-
sectional associations in rheumatoid arthritis. Arthritis Res Ther
17:237
12. Pollard LC, Ibrahim F, Choy EH, Scott DL (2012) Pain thresholds
in rheumatoid arthritis: the effect of tender point counts and disease
duration. J Rheumatol 39(1):28–31
13. Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH,
Yarnitsky D, Freeman R, Truini A, Attal N, Finnerup NB,
EcclestonC (2017) Neuropathic pain. Nat RevDis Primers 3:17002
14. O’Connor AB (2009) Neuropathic pain. Pharmacoeconomics.
27(2):95–112
15. HaanpääML, BackonjaMM,Bennett MI, Bouhassira D, CruccuG,
Hansson PT, Jensen TS, Kauppila T, Rice AS, Smith BH, Treede
RD (2009) Assessment of neuropathic pain in primary care. Am J
Med 122(10):S13–S21
16. Greenspan JD (2001) Quantitative assessment of neuropathic pain.
Curr Pain Headache Rep 5(2):107–113
Clin Rheumatol (2019) 38:3153–31593158
17. Freynhagen R, Baron R, Gockel U, Tölle TR (2006) painDETECT:
a new screening questionnaire to identify neuropathic components
in patients with back pain. Curr Med Res Opin 22(10):1911–1920
18. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS,
Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB (2010)
The American College of Rheumatology preliminary diagnostic
criteria for fibromyalgia and measurement of symptom severity.
Arthritis Care Res 62(5):600–610
19. Wolfe F, Brähler E, Hinz A, Häuser W (2013) Fibromyalgia prev-
alence, somatic symptom reporting, and the dimensionality of
polysymptomatic distress: results from a survey of the general pop-
ulation. Arthritis Care Res 65(5):777–785
20. Tan G, Jensen MP, Thornby JI, Shanti BF (2004) Validation of the
Brief Pain Inventory for chronic nonmalignant pain. J Pain 5(2):
133–137
21. Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF
(1994) Measuring the functional impact of fatigue: initial validation
of the fatigue impact scale. Clin Infect Dis 18(Supplement_1):S79–
S83
22. Jason LA, Evans M, Brown M, Porter N, Brown A, Hunnell J,
Anderson V, Lerch A (2011) Fatigue scales and chronic fatigue
syndrome: issues of sensitivity and specificity. Disabil Stud Q
31(1):pii1375
23. Bjelland I, Dahl AA, Haug TT, Neckelmann D (2002) The validity
of the Hospital Anxiety and Depression Scale: an updated literature
review. J Psychosom Res 52(2):69–77
24. Bruce B, Fries JF (2005) The health assessment questionnaire
(HAQ). Clin Exp Rheumatol 23(5):S14
25. Freynhagen R, Baron R, Gockel U, Tölle TR (2006) Pain
DETECT: a new screening questionnaire to identify neuropathic
components in patients with back pain. CurrMed Res Opin 22(10):
1911–1920
26. Choy EH, Khoshaba B, Cooper D, MacGregor A, Scott DL (2008)
Development and validation of a patient-based disease activity
score in rheumatoid arthritis that can be used in clinical trials and
routine practice. Arthritis Rheum 59(2):192–199
27. Somedic SenseLab. Algometer. [Date unknown] Available at:
http://somedic.com/en/algometer.html Accessed 12/05/19
28. North Coast Medical Inc. Touch Test ® Sensory Evaluators. 2019;
Available at: https://www.ncmedical.com/item_1278.html
Accessed 12/05/19
29. Abiebr. Hospital Anxiety and Depression Scale. 2017; Available at:
http://www.abiebr.com/node/410. Accessed 07/12, 2017
30. Campbell JN, Meyer RA (2006) Mechanisms of neuropathic pain.
Neuron. 52(1):77–92
31. Rifbjerg-Madsen S, Christensen AW, Christensen R, Hetland ML,
Bliddal H, Kristensen LE, Danneskiold-Samsøe B, Amris K (2017)
Pain and pain mechanisms in patients with inflammatory arthritis: a
Danish nationwide cross-sectional DANBIO registry survey. PLoS
One 12(7):e0180014
32. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W,
Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB (2011)
Fibromyalgia criteria and severity scales for clinical and epidemio-
logical studies: a modification of the ACR Preliminary Diagnostic
Criteria for Fibromyalgia. J Rheumatol 38(6):1113–1122
33. Gauffin J, Hankama T, Kautiainen H, Hannonen P, Haanpää M
(2013) Neuropathic pain and use of Pain DETECT in patients with
fibromyalgia: a cohort study. BMC Neurol 13(1):21
34. Magrey MN, Antonelli M, James N, Khan MA (2013) High fre-
quency of fibromyalgia in patients with psoriatic arthritis: a pilot
study. Arthritis. 2013:1–4
35. Brikman S, Furer V, Wollman J, Borok S, Matz H, Polachek A,
Elalouf O, Sharabi A, Kaufman I, Paran D, Elkayam O (2016) The
effect of the presence of fibromyalgia on common clinical disease
activity indices in patients with psoriatic arthritis: a cross-sectional
study. J Rheumatol 43(9):1749–1754
36. Marchesoni A, Atzeni F, Spadaro A, Lubrano E, Provenzano G,
Cauli A, Olivieri I, Melchiorre D, Salvarani C, Scarpa R, Sarzi-
Puttini P (2012) Identification of the clinical features distinguishing
psoriatic arthritis and fibromyalgia. J Rheumatol 39(4):849–855
37. Koroschetz J, Rehm SE, Gockel U, Brosz M, Freynhagen R, Tölle
TR, Baron R (2011) Fibromyalgia and neuropathic pain-differences
and similarities. A comparison of 3057 patients with diabetic pain-
ful neuropathy and fibromyalgia. BMC Neurol 11(1):55
38. Rehm SE, Koroschetz J, Gockel U, Brosz M, Freynhagen R, Tölle
TR, Baron R (2010) A cross-sectional survey of 3035 patients with
fibromyalgia: subgroups of patients with typical comorbidities and
sensory symptom profiles. Rheumatology. 49(6):1146–1152
39. Amris K, Jespersen A, Bliddal H (2010) Self-reported somatosen-
sory symptoms of neuropathic pain in fibromyalgia and chronic
widespread pain correlate with tender point count and pressure-
pain thresholds. PAIN® 151(3):664–669
40. Greene DA, Stevens MJ, Feldman EL (1999) Diabetic neuropathy:
scope of the syndrome. Am J Med 107(2):2–8
41. Said G (2007) Diabetic neuropathy—a review. Nat Rev Neurol
3(6):331
42. Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ
(2011) Prevalence and characteristics of painful diabetic neuropa-
thy in a large community-based diabetic population in the UK.
Diabetes Care 34(10):2220–2224
43. Kudel I, Hopps M, Cappelleri JC, Sadosky A, King-Concialdi K,
Liebert R, Parsons B, Hlavacek P, Alexander AH, DiBonaventura
MD, Markman JD (2019) Characteristics of patients with neuro-
pathic pain syndromes screened by the painDETECT questionnaire
and diagnosed by physician exam. J Pain Res 12:255–268
44. Dreiher J, Freud T, Cohen AD (2013) Psoriatic arthritis and diabe-
tes: a population-based cross-sectional study. Dermatol Res Pract
2013:1–7
45. Jones GT, Atzeni F, Beasley M, Flüß E, Sarzi-Puttini P, Macfarlane
GJ (2015) The prevalence of fibromyalgia in the general popula-
tion: a comparison of the American College of Rheumatology
1990, 2010, and modified 2010 classification criteria. Arthritis
Rheum 67(2):568–575. https://doi.org/10.1002/art.38905
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
Clin Rheumatol (2019) 38:3153–3159 3159
